People in the News
Bill Castell, CEO of GE Healthcare, will retire next year. Castell's plans were included in an announcement earlier this month about the realigning of GE's 11 business units into six industry-focused businesses: GE Infrastructure; GE Industrial; GE Commercial Financial Services; NBC Universal; GE Healthcare; and GE Consumer Finance.
Castell will remain the head of GE Healthcare and a member of the board of directors until his retirement, at which time Joe Hogan will take over as president and CEO of GE Healthcare. Hogan has served as president and CEO of the Waukesha, Wisc.-based GE Healthcare Technologies division, once known as GE Medical Systems, since 2000, when he succeeded Jeff Immelt. Immelt was promoted to succeed Jack Welch as head of GE.
The Sunday Times of London reported last weekend that Castell may take the reins of the Wellcome Trust when its current chairman, Sir Dominic Cadbury, retires. A Wellcome Trust spokesperson told BioArray News' sister publication GenomeWeb Daily News that this report is "speculation," and that the UK-based medical research charity is still trying to "identify suitable people" to replace Cadbury.
Peter Leddy has joined Invitrogen as senior vice president of human resources. He most recently served as vice president of human resources for the Americas operations of Dell. Leddy will oversee Invitrogen's global HR strategy and report directly to CEO Greg Lucier.
New Product Watch
Precision System Science last week announced that it has developed its Magtration System 12XP for sample preparation in DNA microarray experiments.
The system is based on PSS's proprietary technology for nucleic acid extraction using magnetic particles and automates preprocessing procedures required for DNA, the company said.
PSS also said that Amersham Biosciences, a Japanese subsidiary of GE Healthcare, will collaborate in sales of the system and will supply PSS with its proprietary reagents for cDNA and cRNA synthesis. The combined system will be available in Spring 2006.
Greiner Bio-One late last month introduced its line of streptavidin-coated Microplates through its Longwood, Fla.-based US office (see related story, this issue).
he microplates are available in 96- and 384-well formats and use the streptavidin-biotin bond for bonding biotinylated protein, nucleic acid, and antigen-antibodies onto pre-coated streptavidin plates.